Kumarasamypet Murugesan Mohankumar

Kumarasamypet Murugesan Mohankumar

Auto-generated profile, based on publicly available information

Kumarasamypet Murugesan Mohankumar

Centre for Stem Cell Research (a Unit of inStem, Bengaluru), Christian Medical College Campus, Vellore, India

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2014 in Nature
Verified
Journal Article
Open access
PDF file
MPMatthew Parker
Matthew Parker
KMKumarasamypet M. Mohankumar
Kumarasamypet M. Mohankumar
CPChandanamali Punchihewa
Chandanamali Punchihewa
RWRicardo Weinlich
Ricardo Weinlich
JDJames D. Dalton
James D. Dalton
RGRichard J. Gilbertson
Richard J. Gilbertson
Members of the nuclear factor-κB (NF-κB) family of transcriptional regulators are central mediators of the cellular inflammatory response. Although constitutive NF-κB signalling is present in most human tumours, mutations in pathway members are rare, complicating efforts to understand and block aberrant NF-κB activity in cancer. Here we show that more than two-thirds of supratentorial ependymomas contain oncogenic fusions between RELA, the principal effector of canonical NF-κB signalling, and an uncharacterized gene, C11orf95. In each case, C11orf95–RELA fusions resulted from chromothripsis involving chromosome 11q13.1. C11orf95–RELA fusion proteins translocated spontaneously to the nucleus to activate NF-κB target genes, and rapidly transformed neural stem cells—the cell of origin of ependymoma—to form these tumours in mice. Our data identify a highly recurrent genetic alteration of RELA in human cancer, and the C11orf95–RELA fusion protein as a potential therapeutic target in supratentorial ependymoma.

18 July 2010 in Nature
Verified
Journal Article
Open access
PDF file
RJRobert A. Johnson
Robert A. Johnson
KWKaren D. Wright
Karen D. Wright
HPHelen Poppleton
Helen Poppleton
KMKumarasamypet M. Mohankumar
Kumarasamypet M. Mohankumar
DFDavid Finkelstein
David Finkelstein
RGRichard J. Gilbertson
Richard J. Gilbertson
Ependymoma is a type of neural tumour that arises throughout the central nervous system. Using comparative transcriptomics in mouse and human tumours, Johnson et al. home in on mutations that are specific to individual tumour subgroups. In the course of their study, the authors generate the first mouse model of ependymoma and demonstrate the power of interspecific genomic comparisons to interrogate cancer subgroups. Ependymoma is a type of neural tumour that arises throughout the central nervous system. Using comparative transcriptomics in mouse and human tumours, these authors home in on mutations that are specific to individual tumour subgroups. In doing so, they generate the first mouse model of ependymoma and demonstrate the power of interspecific genomic comparisons to interrogate cancer subgroups. Understanding the biology that underlies histologically similar but molecularly distinct subgroups of cancer has proven difficult because their defining genetic alterations are often numerous, and the cellular origins of most cancers remain unknown1,2,3. We sought to decipher this heterogeneity by integrating matched genetic alterations and candidate cells of origin to generate accurate disease models. First, we identified subgroups of human ependymoma, a form of neural tumour that arises throughout the central nervous system (CNS). Subgroup-specific alterations included amplifications and homozygous deletions of genes not yet implicated in ependymoma. To select cellular compartments most likely to give rise to subgroups of ependymoma, we matched the transcriptomes of human tumours to those of mouse neural stem cells (NSCs), isolated from different regions of the CNS at different developmental stages, with an intact or deleted Ink4a/Arf locus (that encodes Cdkn2a and b). The transcriptome of human supratentorial ependymomas with amplified EPHB2 and deleted INK4A/ARF matched only that of embryonic cerebral Ink4a/Arf−/− NSCs. Notably, activation of Ephb2 signalling in these, but not other, NSCs generated the first mouse model of ependymoma, which is highly penetrant and accurately models the histology and transcriptome of one subgroup of human supratentorial tumour. Further, comparative analysis of matched mouse and human tumours revealed selective deregulation in the expression and copy number of genes that control synaptogenesis, pinpointing disruption of this pathway as a critical event in the production of this ependymoma subgroup. Our data demonstrate the power of cross-species genomics to meticulously match subgroup-specific driver mutations with cellular compartments to model and interrogate cancer subgroups.

1 September 2011 in Cancer Cell
Verified
Journal Article
Closed access
JAJennifer M. Atkinson
Jennifer M. Atkinson
ASAnang A. Shelat
Anang A. Shelat
ACAngel Carcaboso
Angel Carcaboso
TKTanya A. Kranenburg
Tanya A. Kranenburg
Leggy ArnoldLeggy Arnold
Leggy Arnold
RGRichard J. Gilbertson
Richard J. Gilbertson

26 June 2007 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DEDenis A. Evseenko
Denis A. Evseenko
PMPadma Murthi
Padma Murthi
JPJames W. Paxton
James W. Paxton
GRGlen Reid
Glen Reid
SBStarling Emerald Bright
Starling Emerald Bright
JKJeffrey Andrew Keelan
Jeffrey Andrew Keelan
The efflux pump ATP binding cassette superfamily member G2 (ABCG2)/breast cancer resistance protein (BCRP) is highly expressed in human placenta. We have investigated the role of BCRP in the protection of the human placental trophoblasts from apoptosis and its expression in idiopathic fetal growth restriction, a condition associated with abnormal pla‐cental apoptosis. Inhibition of BCRP activity with the selective inhibitor Ko143 augmented cytokine (tumor necrosis factor‐α/interferon‐γ)‐induced apoptosis and phosphatidylserine externalization in primary tropho‐blast and trophoblast‐like BeWo cells. Silencing of BCRP expression in BeWo cells significantly increased their sensitivity to apoptotic injury in response to cytokines and exogenous C6 and C8 ceramides. BCRP silencing also increased intracellular ceramide levels after cytokine exposure but did not affect cellular protoporphyrin IX concentrations or sensitivity to activators of the intrinsic apoptotic pathway. BCRP expression in placentas from pregnancies complicated by idiopathic fetal growth restriction was decreased compared with controls, suggesting reduced transport of its substrates from the placenta. We conclude that BCRP may play a hitherto unrecognized survival role in the placenta, protecting the trophoblast against cytokine‐induced apoptosis and possibly other extrinsic activators via modulation of ceramide signaling. Decreased placental BCRP expression may result in reduced viability and hence functional deficit, contributing to the fetal growth restriction phenotype.—Evseenko, D. A., Murthi, P., Paxton, J. W., Reid, G., Emerald, B. S., Mohankumar, K. M., Lobie, P. E., Brennecke, S. P., Kalionis, B. Keelan, J. A. The ABC transporter BCRP/ ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J. 21, 3592–3605 (2007)

1 May 2008 in Endocrinology
Verified
Journal Article
Open access
PDF file
VPVijay Pandey
Vijay Pandey
Jo K. PerryJo K. Perry
Jo K. Perry
KMKumarasamypet M. Mohankumar
Kumarasamypet M. Mohankumar
XKXiang-Jun Kong
Xiang-Jun Kong
SLShu-Min Liu
Shu-Min Liu
PLPeter E. Lobie
Peter E. Lobie
Recent published data have demonstrated elevated levels of human GH (hGH) in endometriosis and endometrial adenocarcinoma. Herein, we demonstrate that autocrine production of hGH can enhance the in vitro and in vivo oncogenic potential of endometrial carcinoma cells. Forced expression of hGH in endometrial carcinoma cell lines RL95-2 and AN3 resulted in an increased total cell number through enhanced cell cycle progression and decreased apoptotic cell death. In addition, autocrine hGH expression in endometrial carcinoma cells promoted anchorage-independent growth and increased cell migration/invasion in vitro. In a xenograft model of human endometrial carcinoma, autocrine hGH enhanced tumor size and progression. Changes in endometrial carcinoma cell gene expression stimulated by autocrine hGH was consistent with the altered in vitro and in vivo behavior. Functional antagonism of hGH in wild-type RL95-2 cells significantly reduced cell proliferation, cell survival, and anchorage-independent cell growth. These studies demonstrate a functional role for autocrine hGH in the development and progression of endometrial carcinoma and indicate potential therapeutic relevance of hGH antagonism in the treatment of endometrial carcinoma.

1 December 2010 in Neoplasia
Verified
Journal Article
Open access
PDF file
Kannan NagarajanKannan Nagarajan
Kannan Nagarajan
JKJian Kang
Jian Kang
XKXiangjun Kong
Xiangjun Kong
JTJianzhong Tang
Jianzhong Tang
Jo K. PerryJo K. Perry
Jo K. Perry
PLPeter E. Lobie
Peter E. Lobie
Neoplasia publishes the results of novel investigations in all areas of oncology research.